一种用于筛选酒精使用障碍药物的新型人类实验室模型
本研究旨在开发并验证一种受戒烟文献启发的早期疗效范式,用于筛选酒精使用障碍(AUD)新药。研究将纳入有改变饮酒动机的AUD患者,随机双盲接受纳曲酮、伐尼克兰或安慰剂,完成一周「实践性戒烟尝试」及线索反应性测试。成功验证该模型可加速AUD药物开发中的早期决策。
要点
- 该范式结合实验室内在效度与临床试验外在效度,用于早期疗效筛选。
- 纳曲酮作为活性对照,伐尼克兰作为待测药物,安慰剂对照。
- 主要评估饮酒、渴求及情绪等指标,含两次酒精线索反应性测试。
核心结论
- 开发并验证一种新型早期疗效模型,用于筛选AUD药物疗法,可辅助做出是否进入临床试验的go/no-go决策。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入当前AUD且有内在改变动机的个体,随机分配至纳曲酮、伐尼克兰或安慰剂组。
- 参与者在服药期间完成一周「实践性戒烟尝试」,期间每日电话访视并填写在线问卷,另进行两次酒精线索反应性测试。
关键数值与推荐
- 纳曲酮作为已建立的AUD药物用作活性对照,伐尼克兰作为有前景的AUD药物疗效测试。
- 试验注册号:ClinicalTrials.gov NCT04249882,注册日期2020年1月31日。
临床怎么用
- 该模型若验证成功,可为AUD新药早期筛选提供更高效且具临床意义的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alcohol use disorder (AUD) is a highly prevalent, chronic relapsing disorder with a high disease burden in the USA. Pharmacotherapy is a promising treatment method for AUD; however, the few FDA-approved medications are only modestly effective. Medications development for AUD is a high priority research area, but the cumbersome drug development process hinders many potential compounds from reaching approval. One area with major opportunities for improvement is the process of screening novel compounds for initial efficacy, also known as early phase 2 trials. Early phase 2 trials incorporate human laboratory paradigms to assess relevant clinical constructs, such as craving and subjective responses to alcohol. However, these controlled paradigms often lack the ecological validity of clinical trials. Therefore, early phase 2 trials can be more efficient and clinically meaningful if they combine the internal validity of experimental laboratory testing with the external validity of clinical trials. To that end, the current study aims to develop and validate a novel early efficacy paradigm, informed by smoking cessation literature, to screen novel medications for AUD. As an established AUD medication, naltrexone will serve as an active control to test both the practice quit attempt model and the efficacy of a promising AUD pharmacotherapy, varenicline. METHODS: Individuals with current AUD reporting intrinsic motivation to change their drinking will complete a week-long "practice quit attempt" while on study medication. Participants are randomized and blinded to either naltrexone, varenicline, or placebo. During the practice quit attempt, participants will complete daily visits over the phone and fill out online questionnaires regarding their drinking, alcohol craving, and mood. Additionally, participants will undergo two alcohol cue-reactivity sessions. DISCUSSION: The successful completion of this study will advance medications development by proposing and validating a novel early efficacy model for screening AUD pharmacotherapies, which in turn can serve as an efficient strategy for making go/no-go decisions as to whether to proceed with clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT04249882 . Registered on 31 January 2020.
引用
- Ho D, Towns B, Grodin EN, et al. A novel human laboratory model for screening medications for alcohol use disorder. Trials. 2020. PMID: 33225963. doi:10.1186/s13063-020-04842-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。